ROS1 and non-small cell lung carcinoma: Although evidence in ROS1 fusion positive NSCLC is limited, a global registry has shown limited ORR of immune checkpoint inhibitors in NSCLC harboring oncogenic alterations with reported ORR of ROS1 fusion + patients being 17% (n = 7) and 12% (n = 125) for EGFR mutated patients [33].